A Blue Light-Inducible CRISPR-Cas9 System for Inhibiting Progression of Melanoma Cells

Wu, Xia; Huang, Haiyan; Yu, Bo; Zhang, Jianzhong

doi:10.3389/fmolb.2020.606593

Cited by 15 publications

(14 citation statements)

References 33 publications

(33 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Once the cells are irradiated with blue light, the GAL(65)-VVD-p65 fusion peptide forms an active transcriptional activator that binds the UAS-responsive element, and the Cas9 gene is transcribed. With these innovative controllable CRISPR/Cas9 systems, the authors managed to suppress cell growth, migration, and invasion, and induce apoptosis in the A375 and G361 melanoma cells that harbor the BRAF V600E mutation [ 62 ]. Such strategy might also prove to be useful for targeting this mutation in other types of malignant disorders, such as colorectal cancer [ 63 ].…”

Section: Approaches For Therapeutic Genome Editing In Human Malignant...mentioning

confidence: 99%

Genome Editing Approaches with CRISPR/Cas9 for Cancer Treatment: Critical Appraisal of Preclinical and Clinical Utility, Challenges, and Future Research

Chira

Nuțu

Isacescu

et al. 2022

Cells

View full text Add to dashboard Cite

The increasing burden on human malignant diseases became a major concern for healthcare practitioners, that must deal with tumor relapse and the inability to efficiently treat metastasis, in addition to side effects. Throughout the decades, many therapeutic strategies have been employed to improve the clinical outcomes of cancer patients and great efforts have been made to develop more efficient and targeted medicines. The malignant cell is characterized by genetic and epigenetic modifications, therefore targeting those specific drivers of carcinogenesis is highly desirable. Among the genome editing technologies, CRISPR/Cas9 stood as a promising candidate for cancer treatment alternatives, due to its low complexity design. First described as a defense mechanism of bacteria against invading foreign DNA, later it was shown that CRISPR components can be engineered to target specific DNA sequences in a test tube, a discovery that was awarded later with the Nobel Prize in chemistry for its rapid expansion as a reliable genome editing tool in many fields of research, including medicine. The present paper aims of describing CRISPR/Cas9 potential targets for malignant disorders, and the approaches used for achieving this goal. Aside from preclinical studies, we also present the clinical trials that use CRISPR-based technology for therapeutic purposes of cancer. Finally, a summary of the presented studies adds a more focused view of the therapeutic value CRISPR/Cas9 holds and the associated shortcomings.

show abstract

Section: Approaches For Therapeutic Genome Editing In Human Malignant...mentioning

confidence: 99%

Genome Editing Approaches with CRISPR/Cas9 for Cancer Treatment: Critical Appraisal of Preclinical and Clinical Utility, Challenges, and Future Research

Chira

Nuțu

Isacescu

et al. 2022

Cells

View full text Add to dashboard Cite

show abstract

“…As BRAF mutations are more common in melanoma, studies utilizing CRISPR/Cas9 for chemotherapeutic agents have often revolved around the melanoma. Wu et al developed a light-inducible CRISPR/Cas9 system to cleave the mutated BRAF gene (BRAF V600E), which promotes melanoma cell apoptosis and effectively inhibits melanoma cell proliferation, invasion, and migration ( Wu et al, 2020 ).…”

Section: Principles Of Multidrug Resistance In Nsclc Reversed By Cris...mentioning

confidence: 99%

Application and Prospect of CRISPR/Cas9 Technology in Reversing Drug Resistance of Non-Small Cell Lung Cancer

et al. 2022

View full text Add to dashboard Cite

Cancer drug resistance has always been a major factor affecting the treatment of non-small cell lung cancer, which reduces the quality of life of patients. The clustered regularly interspaced short palindromic repeats/CRISPR associated protein 9 (CRISPR/Cas9) technology, as an efficient and convenient new gene-editing technology, has provided a lot of help to the clinic and accelerated the research of cancer and drug resistance. In this review, we introduce the mechanisms of drug resistance in non-small cell lung cancer (NSCLC), discuss how the CRISPR/Cas9 system can reverse multidrug resistance in NSCLC, and focus on drug resistance gene mutations. To improve the prognosis of NSCLC patients and further improve patients’ quality of life, it is necessary to utilize the CRISPR/Cas9 system in systematic research on cancer drug resistance.

show abstract

“…In addition to PBM and PDT, it is worth noting that PBM can also be combined with gene editing and optogenetics to improve the efficiency of treating melanoma. Wu et al used blue light combined with the CRISPR‐Cas9 System to inhibit melanoma cell progression 90 . Zhang et al demonstrated that blue light‐triggered optogenetic system for treating uveal melanoma 91 .…”

Section: Future Studiesmentioning

confidence: 99%

The review of the light parameters and mechanisms of Photobiomodulation on melanoma cells

Chen

Huang

Liu

2021

Photoderm Photoimm Photomed

View full text Add to dashboard Cite

Photobiomodulation (PBM) uses low‐intensity visible or near‐infrared light to produce beneficial effects on cells or tissues, such as brain therapy, wound healing. Still there is no consistent recommendation on the parameters (dose, light mode, wavelength, irradiance) and protocols (repetition, treatment duration) for its clinical application. Herein, we summarize the current PBM parameters for the treatment of melanoma, and we also discuss the potential photoreceptors and downstream signaling mechanisms in the PBM treatment of melanoma cells. It is hypothesized that PBM may inhibit the melanoma cells by activating mitochondria, OPNs, and other receptors. Regardless of the underlying mechanisms, PBM has been shown to be beneficial in treating melanoma. Through further in‐depth studies of the underlying potential mechanisms, it can strengthen the applications of PBM for the therapy of melanoma.

show abstract

A Blue Light-Inducible CRISPR-Cas9 System for Inhibiting Progression of Melanoma Cells

Cited by 15 publications

References 33 publications

Genome Editing Approaches with CRISPR/Cas9 for Cancer Treatment: Critical Appraisal of Preclinical and Clinical Utility, Challenges, and Future Research

Genome Editing Approaches with CRISPR/Cas9 for Cancer Treatment: Critical Appraisal of Preclinical and Clinical Utility, Challenges, and Future Research

Application and Prospect of CRISPR/Cas9 Technology in Reversing Drug Resistance of Non-Small Cell Lung Cancer

The review of the light parameters and mechanisms of Photobiomodulation on melanoma cells

Contact Info

Product

Resources

About